Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|July 21, 2015

Shimadzu Scientific Instruments Names Katsuaki Kaito as President

Katsuaki Kaito has been named president of Shimadzu Scientific Instruments.

Shimadzu Corporation announced on July 21 that it has named Katsuaki Kaito president of Shimadzu Scientific Instruments (SSI). Kaito will be responsible for all sales and management functions for SSI, the American subsidiary of Shimadzu Corporation (Kyoto, Japan). He takes the place of former SSI president Shuzo Maruyama, who has been promoted to general manager of the analytical and measuring division.

Kaito joined the company’s liquid chromatography department 32 years ago and has spent 14 years performing R&D functions and 18 years in manufacturing. He was president of Shimadzu USA Manufacturing from 2003 to 2008; since then, he has served as general manager of the analytical and measuring instruments plant.

Kaito earned a degree in mechanical engineering from the University of Tokyo.

Source: Shimadzu Scientific Instruments

 

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more